PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders

Sinah Engel, Felix Luessi, Aneka Mueller, Rudolf E. Schopf, Frauke Zipp and Stefan Bittner

Abstract: Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descriptions of monophasic demyelinating events or cases of relapsing–remitting MS (RRMS). We here provide the first case report of primary progressive MS (PPMS) onset upon anti-TNF-α therapy as well as a literature review of previously published cases of anti-TNF-α therapy-associated MS onset. The 51-year old male patient was treated with adalimumab due to psoriasis arthritis. About 18 months after treatment initiation, he developed slowly progressing neurological deficits including gait impairment, paraesthesia of the lower limbs, stranyrgy and visual impairment, which led to the discontinuation of adalimumab therapy. Magnetic resonance imaging of the brain and the spinal cord revealed multiple inflammatory lesions and cerebrospinal fluid examination showed slight pleocytosis and positive oligoclonal bands. Thus, PPMS was diagnosed according to the 2017 revision of the McDonald criteria. As PPMS often causes only subtle symptoms in the beginning and early treatment discontinuation of anti-TNF-α therapy seems essential to improve the patient’s outcome, we think that it is important to increase the awareness of slowly progressing neurological deficits as a potential adverse event of anti-TNF-α therapy among all clinicians involved in the initiation and monitoring of these drugs. In addition, the occurrence of both RRMS and progressive MS upon anti-TNF-α therapy might suggest a shared TNF-α-mediated pathophysiological mechanism in the evolution of all MS subtypes.

Keywords: adalimumab, anti-TNF-alpha therapy, primary progressive multiple sclerosis

Received: 8 July 2019; revised manuscript accepted: 4 November 2019.

Introduction

Anti-tumour necrosis factor-α (anti-TNF-α) agents such as adalimumab (Humira®) are commonly used in the treatment of rheumatological, dermatological and gastroenterological autoimmune disorders. Despite being generally considered to be well tolerated, serious autoimmune-mediated adverse events have been reported, including central nervous system (CNS) demyelinating disorders such as multiple sclerosis (MS). In formerly published MS cases associated with anti-TNF-α use, authors either diagnosed relapsing–remitting MS (RRMS) or the descriptions did not offer enough information to classify the disease course. We here describe the first occurrence of well-defined and definite primary progressive MS (PPMS) upon anti-TNF-α therapy and provide an overview of the current literature concerning this topic.

Case report

In November 2018, a 51-year old White man was first admitted to our hospital due to progressive neurological deficits. He was first diagnosed with...
psoriasis vulgaris in the 1980s and was initially treated topically with steroids, dithranol and phototherapy, followed by systemic therapy with fumarate, cyclosporine, and methotrexate. Owing to signs of psoriasis arthritis, anti-TNF-α treatment with adalimumab was initiated in September 2015, leading to almost complete remission of the psoriasis.

However, in early 2017, about 18 months after treatment initiation, the patient first perceived hypesthesia of the lower limbs [corresponding to an Expanded Disability Status Scale (EDSS) score of 2.0], which progressed slowly over the following months. Adalimumab treatment was therefore discontinued in April 2017. Over the course of approximately 1 year, slowly progressive gait impairment, strangury, visual impairment and dysarthria occurred subsequently. Neurological examination in November 2018 revealed gait impairment owing to spasticity and ataxia with a restricted walking distance of about 2 km, severe pall hypaesthesia and brain stem symptoms including saccadic eye movement and dysarthria (corresponding to an EDSS score of 4.0). Visually evoked potentials (VEPs) displayed prolonged latencies of both optic nerves. Magnetic resonance imaging (MRI) of the brain and spinal cord showed numerous T2-hyperintensive lesions without contrast enhancement in periventricular, juxtacortical and spinal localization (Figure 1A–D). Cerebrospinal fluid (CSF) analysis revealed a slight pleocytosis, intrathecal immunoglobulin synthesis, and presence of CSF-specific oligoclonal bands. Tests for serum antibodies against Aquaporin-4 and MOG were negative. Infectious or other autoimmunological causes were ruled out.

As the patient fulfilled all diagnostic criteria according to the 2017 revision of the McDonald criteria (progressive neurological symptoms >12 months, MRI lesions typical for MS, positive CSF and pathologic VEPs), PPMS was diagnosed. Disease-modifying treatment with ocrelizumab was initiated and complemented by topical steroids for treating psoriatic symptoms.

The patient had no family history of multiple sclerosis or other neurological diseases. He gave written informed consent for both performing genomic sequencing and publishing its results, along with clinical data, radiological findings and results of laboratory tests in this case report.

**Review of reported cases**

As anti-TNF-α therapy-associated demyelinating disorders, including monophasic demyelinating events and peripheral demyelinating syndromes, have already been reviewed extensively in the past, we focused on those reports describing a definite diagnosis of MS (Table 1).

We identified 20 cases of MS onset upon anti-TNF-α therapies, of which 9 were diagnosed with RRMS according to the McDonald criteria. In 8 further cases, MS disease course was described as RRMS, but diagnostic criteria were not specified. One case could not be classified owing to a paucity of clinical data. There was one case description of slowly progressing neurological deficits, in which the available clinical information allowed no differentiation between secondary and primary progressive disease course, and one report about the exacerbation of preexisting PPMS in a patient treated with etanercept. Four patients had a positive family history for MS.

**Discussion**

MS is a heterogeneous disease, which may be categorized into clinically isolated syndrome (CIS), RRMS, secondary progressive MS (SPMS) and PPMS. Lately, there have been suggestions to also include radiologically isolated syndrome (RIS), which is defined by MRI lesions suggestive for MS without clinical manifestation, as a pre- or co-rome of MS diseases since around one-third of patients with asymptomatic lesions develops neurological symptoms later on. Interestingly, some RIS patients progress directly to PPMS. This supports the hypothesis that all MS subtypes share some biological aspects in their pathogenesis, although it is still unknown why some patients suffer from acute relapses, whereas others progress relapse independently.

Although the possibility that the patient reported here had preexisting MS that was unmasked by adalimumab treatment, or that PPMS onset occurred coincidentally with adalimumab therapy cannot be fully excluded, our case suggests a crucial role of deregulated TNF-α homeostasis in the evolution of all MS subtypes as it offers the first description of definite PPMS onset upon anti-TNF-α therapy and thereby extends the spectrum of demyelinating diseases associated with these drugs.
| Reference                  | Sex/age | Primary autoimmune disease | Anti-TNF-α agent | MS disease course | According to diagnostic criteria | Family history for MS | Treatment                          | Disability outcome                  |
|----------------------------|---------|-----------------------------|------------------|-------------------|----------------------------------|----------------------|-----------------------------------|--------------------------------------|
| Al Saieg and Luzar         | F/58    | RA                          | Etanercept       | Relapsing–remitting | Not specified                     | None                 | Discontinuation and steroids      | Full recovery from relapse           |
| Andreadou et al.           | M/17    | PsA                         | Etanercept       | Relapsing–remitting | McDonald 2010                     | None                 | Discontinuation and steroids      | Nearly full recovery from relapse    |
| Andreadou et al.           | M/30    | AS                          | Adalimumab       | Relapsing–remitting | McDonald 2010                     | Father with MS       | Discontinuation and steroids      | Full recovery from relapse           |
| Andreadou et al.           | F/57    | AS                          | Etanercept       | Relapsing–remitting | McDonald 2010                     | None                 | Discontinuation and steroids      | Partial recovery from relapse        |
| Davis et al.               | M/53    | PsA                         | Etanercept       | Relapsing–remitting | Not specified                     | None                 | Discontinuation and interferon–beta | Partial recovery from relapse        |
| Davis et al.               | M/42    | PsA                         | Etanercept       | Relapsing–remitting | Not specified                     | None                 | Discontinuation                   | Partial recovery from relapse        |
| Fromont et al.             | F/49    | RA                          | Etanercept       | Relapsing–remitting | McDonald 2005                     | None                 | Discontinuation and interferon–beta | No data                             |
| Bensouda-Grimaldi et al.   | F/32    | RA                          | Adalimumab       | Relapsing–remitting | McDonald 2005                     | None                 | Discontinuation and steroids      | Partial recovery from relapse        |
| Matsumoto et al.           | F/68    | RA                          | Adalimumab       | Relapsing–remitting | McDonald 2010                     | None                 | Discontinuation                   | Full recovery from relapse           |
| Ruiz-Jimeno et al.         | F/47    | PsA                         | Infliximab       | Relapsing–remitting | Not specified                     | Sister with MS       | Steroids and IVIGs                | Partial recovery from relapse        |
| Titelbaum et al.           | F/33    | RA                          | Etanercept       | Relapsing–remitting | Not specified                     | None                 | Discontinuation                   | No data                             |
| Uygunoglu et al.           | M/36    | AS                          | Adalimumab       | Relapsing–remitting | McDonald 2010                     | None                 | Discontinuation and steroids      | Full recovery from relapse           |
| Pfueller et al.            | F/36    | AS                          | Etanercept       | Relapsing–remitting | McDonald 2010                     | None                 | Discontinuation                   | Full recovery from relapse           |
| Alnasser Alsukhni et al.   | M/23    | Autoimmune uveitis          | Adalimumab       | Relapsing–remitting | Not specified                     | Two uncles with MS   | Discontinuation and steroids      | Full recovery from relapse           |
| Hare et al.                | F/26    | Crohn’s disease             | Infliximab and adalimumab | Relapsing–remitting | Not specified                     | None                 | Discontinuation, steroids, and plasmapheresis | Partial recovery from relapse       |
| Sicotte and Voskuhl        | F/21    | Juvenile RA                 | Etanercept       | Relapsing–remitting | Not specified                     | None                 | Discontinuation, steroids, and interferon beta | Full recovery from relapse           |
| Gomez-Gallego et al.       | F/36    | PsA                         | Etanercept       | Relapsing–remitting | McDonald 2010                     | None                 | Discontinuation and steroids      | Partial recovery from relapse        |
| Enayati and Papadakis      | F/35    | Inflammatory bowel disease  | Infliximab       | Progressive        | Not specified                     | Father with MS       | No data                           | Rehabilitation necessary            |
| Winkelmann et al.          | M/55    | PsA                         | Etanercept       | Exacerbation of preexisting PPMS | McDonald 2001       | None                 | Discontinuation and steroids      | No recovery                          |
| Cruz Fernandez-Espartero et al. | F/67 | Rheumatic Disease           | Infliximab       | MS, subtype not specified | No data               | None                 | Discontinuation                   | Recovery                            |

AS, ankylosing spondylitis; PsA, psoriasis arthritis; RA, rheumatoid arthritis.
The effects mediated by TNF-α are extremely complex, not least because they can be either pro- or anti-inflammatory depending on cell type-specific interpretation of TNF-triggered pathways. There are also two biologically active variants of TNF-α, a soluble and a transmembrane form, as well as two different receptors. TNF-α-receptor 1 (TNFR1)-activation is mainly associated with pro-inflammatory and cytotoxic signalling, whereas TNF-α-receptor 2 (TNFR2)-activation evokes cytoprotective pathways.28 In MS, TNF-α levels were found to be increased in active MS lesions29 and in an animal model of MS, TNFR1-deficiency led to amelioration of the disease course.30 TNFR2-deficiency on the other hand resulted in enhanced susceptibility.31 It is assumed that the activation of TNFR2 inhibits the pro-inflammatory activity of microglia, promotes the suppressive activity of regulatory T cells, enhances the differentiation of oligodendrocytes and stimulates remyelination.28 It is therefore believed that in MS, in contrast to other autoimmune diseases, an imbalance in favour of pro-inflammatory TNFR1-mediated signalling pathways outweighs beneficial TNFR2-mediated effects.32

Furthermore, genome-wide association studies have identified a link between the development of MS and the presence of the single nucleotide polymorphism (SNP) rs1800693 in the TNFRSF1A gene, which encodes TNFR1.33 Presence of this SNP directs the expression of a novel, soluble form of TNFR1 that can block TNF-α, thus mimicking the effects of anti-TNF-α therapies. Carriers of this SNP might therefore be genetically prone to development or exacerbation of a demyelinating disease upon anti-TNF-α treatment.34 Supporting this hypothesis, our patient was also found to carry the rs1800693 SNP (Figure 1E). Interestingly, no such association has been described for other autoimmune conditions such as rheumatoid arthritis, psoriasis or...
Crohn’s disease, in which anti-TNF-α treatment has a beneficial effect. In the future, genetic testing might be of use to stratify patients according to their individual propensity for developing demyelinating disease upon anti-TNF-α therapy.

We believe that this case of PPMS onset upon adalimumab treatment is of clinical importance as it extends the spectrum of demyelinating disorders associated with anti-TNF-α therapy. In PPMS, neurological deficits are often very subtle in the beginning and usually progress slowly, which may impede diagnosis. However, as early treatment discontinuation is thought to improve the patient’s outcome, it is important to increase the awareness of slowly progressing neurological symptoms as a potential adverse event among all clinicians involved in the initiation and monitoring of anti-TNF-α therapies. In addition, our case supports the hypothesis of a shared pathophysiological mechanism involving dysregulation of TNF-α homeostasis in the evolution of both relapsing and progressing MS.

Acknowledgement
The authors thank Rosalind Gilchrist for proofreading.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Department of Neurology, Focus Program Translational Neuroscience (FTN), and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2) of University Medical Center of the Johannes Gutenberg University Mainz was supported by the German Ministry for Education and Research (BMBF), the German Competence Network Multiple Sclerosis (KKNMS) and the German Research Council (DFG; grant number CRC-TR-128).

Conflict of interest statement
Sinah Engel, Aneka Mueller, Felix Luessi, Frauke Zipp and Stefan Bittner report no conflicts of interest associated with the publication of this manuscript. Rudolf E. Schopf has received honoraria/travel reimbursements from AbbVie, which were not associated with the submitted work.

ORCID iD
Sinah Engel https://orcid.org/0000-0002-9051-9062

References
1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol* 2018; 17: 162–173.
2. Kemanetzoglou E and Andreadou E. CNS demyelination with TNF-alpha blockers. *Curr Neurol Neurosci Rep* 2017; 17: 36.
3. Solomon AJ, Spain RI, Kruer MC, et al. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. *Mult Scler* 2011; 17: 1472–1487.
4. Bosch X, Saiz A, Ramos-Casals M, et al. Monoclonal antibody therapy-associated neurological disorders. *Nat Rev Neurol* 2011; 7: 165–172.
5. Cruz Fernandez-Espartero M, Perez-Zafrilla B, Naranjo A, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. *Semin Arthritis Rheum* 2011; 41: 524–533.
6. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. *Arthritis Rheum* 2001; 44: 2862–2869.
7. Al Saieg N and Luzar MJ. Etanercept induced multiple sclerosis and transverse myelitis. *J Rheumatol* 2006; 33: 1202–1204.
8. Andreadou E, Kemanetzoglou E, Brokalaki C, et al. Demyelinating disease following anti-tnfa treatment: a causal or coincidental association? Report of four cases and review of the literature. *Case Rep Neurol Med* 2013; 2013: 671935.
9. Davis SA, Johnson RR and Pendleton JW. Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies. *J Rheumatol* 2008; 35: 1469–1470.
10. Fromont A, De Seze J, Fleury MC, et al. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. *Cytokine* 2009; 45: 55–57.
11. Bensouda-Grimaldi L, Mulleman D, Valat JP, et al. Adalimumab-associated multiple sclerosis. *J Rheumatol* 2007; 34: 239–240; discussion 240.
12. Matsumoto T, Nakamura I, Miura A, et al. New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. *Clin Rheumatol* 2013; 32: 271–275.
13. Ruiz-Jimeno T, Carvajal A, Mata C, et al. Demyelinating disease in a patient with psoriatic...
14. Titelbaum DS, Degenhardt A and Kinkel RP. Anti-tumor necrosis factor alpha-associated multiple sclerosis. *AJNR Am J Neuroradiol* 2005; 26: 1548–1550.

15. Uygunoglu U, Uluduz D, Tascilar K, et al. Multiple sclerosis during adalimumab treatment in a case with ankylosing spondylitis. *Rheumatol Int* 2014; 34: 141–143.

16. Pfueller CF, Seipel E, Zipp F, et al. Multiple sclerosis following etanercept treatment for ankylosing spondylitis. *Scand J Rheumatol* 2008; 37: 397–399.

17. Alnasser Alsuikhn R, Jriekh Z and Aboras Y. Adalimumab induced or provoked MS in patient with autoimmune uveitis: a case report and review of the literature. *Case Rep Med* 2016; 2016: 1–6.

18. Hare NC, Hunt DP, Venugopal K, et al. Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease. *QJM* 2014; 107: 51–55.

19. Sicotte NL and Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. *Neurology* 2001; 57: 1885–1888.

20. Gomez-Gallego M, Meca-Lallana J and Fernandez-Barreiro A. Multiple sclerosis onset during etanercept treatment. *Eur Neurol* 2008; 59: 91–93.

21. Enayati PJ and Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. *J Clin Gastroenterol* 2005; 39: 303–306.

22. Winkelmann A, Patejdl R, Wagner S, et al. Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. *J Neurol* 2008; 255(Suppl. 6): 109–114.

23. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. *Ann Neurol* 2001; 50: 121–127.

24. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. *Ann Neurol* 2005; 58: 840–846.

25. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol* 2011; 69: 292–302.

26. Okuda DT, Siva A, Kantarci O, et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. *PloS One* 2014; 9: e90509.

27. Kantarci OH, Lebrun C, Siva A, et al. Primary progressive multiple sclerosis evolving from radiologically isolated syndrome. *Ann Neurol* 2016; 79: 288–294.

28. Medler J and Wajant H. Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target. *Expert Opin Ther Targets* 2019; 23: 295–307.

29. Selmaj K, Raine CS, Cannella B, et al. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. *J Clin Invest* 1991; 87: 949–954.

30. Eugster HP, Frei K, Bachmann R, et al. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. *Eur J Immunol* 1999; 29: 626–632.

31. Suvannavejh GC, Lee HO, Padilla J, et al. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG35-55-induced experimental autoimmune encephalomyelitis. *Cell Immunol* 2000; 205: 24–33.

32. Caminero A, Comabella M and Montalban X. Tumor necrosis factor alpha (TNF-alpha), anti-TNF-alpha and demyelination revisited: an ongoing story. *J Neuroimmunol* 2011; 234: 1–6.

33. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. *Nat Genet* 2009; 41: 776–782.

34. Gregory AP, Dendrou CA, Attfield KE, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. *Nature* 2012; 488: 508–511.